

Versajet Reduces Blood Loss During Burn Excision

BY PATRICE WENDLING
Chicago Bureau

CHICAGO — Use of the Versajet Hydrosurgery system was associated with less blood loss and a larger area of excision than was the Goulian-Weck knife in a retrospective study of 50 patients with burn wounds.

The average estimated blood loss was 174 mL for patients who had their wounds excised with the Versajet system, compared with 659 mL for wounds excised with a Goulian-Weck knife. The difference was significant, Dr. Laura S. Johnson said at the annual meeting of the American Burn Association.

The study's primary end point of blood loss in milliliters as a function of area excised in centimeters squared was significantly lower in the Versajet group than in the Goulian-Weck knife group (mean 0.28 cc/cm² vs. 1.75 cc/cm²). This allowed for a significantly greater area of excision in each surgery (mean 622 cm² vs. 379 cm²).

The findings suggest that the Versajet system could allow for earlier excision of burn wounds, perhaps as early as the resuscitation period, Dr. Johnson and her colleagues at the burn center of the Washington (D.C.) Hospital Center concluded.

Dr. James Jeng, associate director of the burn center, said in an interview that they've used the Versajet system since it gained U.S. approval for wound debridement roughly 2 years ago, and that its biggest benefit lies in its ability to discriminate between live and dead tissue.

"This knife is not dumb; it just doesn't cut where you put it, but discriminates between live and dead tissue based on tensile strength," he said. "Necrotic tissue has lower tensile strength, so we can dial down the strength [of the water jet] to partition live from dead tissue. It's pretty much replaced the cold knife for me. This is a poor man's laser ablation."

The Versajet system uses a pressure pump to force a stream of sterile saline through a small jet nozzle at the end of a handpiece, producing both a high-velocity stream and a local vacuum on the surface of the debridement area. The stream

is directed backward across the operating window and into an evacuation collector tube in the handpiece, which also collects any debris or contaminants.

The review included 50 patients (mean age 40 years) with full- and split-thickness burns ranging in percentage of total body surface area from 5% to more than 50%. Excisions were performed as early as day 1, and were carried out over a 6-month period by Dr. Jeng.

Researchers calculated the estimated

blood loss (EBL) by using blood-soaked laparotomy tapes for patients undergoing Goulian-Weck knife excision and by measuring the fluid in the evacuation tube and subtracting the amount of saline used during excision.

Dr. Johnson, a surgical resident, noted that the EBL for the Goulian-Weck knife group was higher than in published reports. However, the EBL for the Versajet group was significantly lower than traditional literature results for early excision,

suggesting that the Versajet system does have benefit during this period, she said.

Dr. Jeng said that pre- and postoperative hematocrit levels don't take into account intraoperative fluid administration and equilibration issues, and that his group is looking into intraoperative optical recording and colorimetric cineanalysis for future studies.

The investigators received no funding for the study, and disclosed no relevant conflicts of interest. ■



Versajet discriminates between live and dead tissue based on tensile strength.

COURTESY DR. JAMES JENG

Cutivate® Lotion...
The Once-a-Day for One and All
First-line therapy for all eczema severities

- **One unique formulation**
 - Enriched with dimethicone to moisturize, protect, and guard against irritation^{1,2}
 - With no evidence of HPA*-axis suppression, skin atrophy, or pigmentation changes^{1,3,4}
 - Available in a convenient 120-mL bottle
- **One application per day** for fast treatment success as early as Week 2^{1,3,5}
- **One year and older**, the broadest age range available for all severities³

Once-daily
CUTIVATE® LOTION, 0.05%
(fluticasone propionate lotion)
Your 1st-Line Choice

*HPA = hypothalamic-pituitary-adrenal.

TFPL30003 was a pivotal, randomized, vehicle lotion-controlled, double-blind, parallel-group study (n=220) in subjects from 3 months to 87 years of age with moderate to severe atopic dermatitis (AD).

CUTIVATE LOTION is indicated for the relief of the inflammatory and pruritic manifestations of atopic dermatitis in patients 1 year of age and older.

Not for ophthalmic, oral, or intravaginal use, or for use by patients with a hypersensitivity to any of its components. In clinical studies, drug-related side effects following the use of CUTIVATE LOTION consisted primarily of localized burning and stinging, and were usually mild and self-limiting. No skin atrophy, changes in pigmentation, or evidence of HPA-axis suppression were observed following the use of CUTIVATE LOTION in these studies. Adrenal suppression has been observed in studies with other fluticasone propionate topical formulations.

References: 1. Eichenfield LF, Miller BH; Cutivate Lotion Study Group. Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from 3 months of age. *J Am Acad Dermatol.* 2006;54:715-717. 2. Uliasz A, Lebowitz M. Dimethicone as a protective ingredient in topical medications. Poster presented at: 65th Annual Meeting of the American Academy of Dermatology; February 2-6, 2007; Washington, DC. 3. Cutivate® Lotion, 0.05% [prescribing information]. Melville, NY: PharmaDerm®, a division of Nycomed US Inc. 2008. 4. Hebert AA, Friedlander SF, Allen DB; Fluticasone Pediatrics Safety Study Group. Topical fluticasone propionate lotion does not cause HPA axis suppression. *J Pediatr.* 2006;149:378-382. 5. Data on file, PharmaDerm.

Please see adjacent page for Brief Summary of Prescribing Information.

CUTIVATE LOTION is a registered trademark of PharmaDerm, a division of Nycomed US Inc.

©2008 PharmaDerm, Melville, NY 11747. All rights reserved. 98NCLD020308


PharmaDerm®
A division of Nycomed US Inc.